研究单位：[1]Xiamen Amoytop Biotech Co., Ltd.[2]Tongji Hospital[3]The Fourth Affiliated Hospital of Anhui Medical University,Hefei,Anhui,China[4]The Second Hospital of Anhui Medical University,Hefei,Anhui,China[5]The First Affiliated Hospital of Xiamen University,Xiamen,Fujian,China[6]Sun Yat-sen Memorial Hospital, Sun Yat-sen University,Guangzhou,Guangdong,China[7]The Third Affiliated Hospital, Sun Yat-sen University,Guangzhou,Guangdong,China[8]Sanya Central Hospital (Hainan Third People's Hospital),Sanya,Hainan,China[9]Henan Children's Hospital Zhengzhou Children's Hospital,Zhengzhou,Henan,China[10]Wuhan Children's Hospital,Wuhan,Hubei,China[11]Hunan Children's Hospital,Changsha,Hunan,China[12]Children's Hospital of Nanjing Medical University,Nanjing,Jiangsu,China[13]Children's Hospital of Soochow University,Suzhou,Jiangsu,China[14]Affiliated Hospital of Jiangnan University,Wuxi,Jiangsu,China[15]Jiangxi Provincial Children's Hospital,Nanchang,Jiangxi,China[16]Chengdu Women's and Children's Central Hospital,Chengdu,Sichuan,China[17]West China Second University Hospital, Sichuan University,Chengdu,Sichuan,China[18]Zhejiang Provincial People's Hospital,Hangzhou,Zhejiang,China[19]Children's Hospital, Capital Institute of Pediatrics,Beijing,China[20]Children's Hospital of Shanghai,Shanghai,China
To explore the dose-response relationship between pharmacokinetics and pharmacodynamics of Y- Shaped Pegylated growth hormone injection (YPEG-GH) in children with short stature (idiopathic short stature (ISS), small for gestational age (SGA), Turner syndrome (TS)). To evaluate its tolerability, safety and efficacy and to provide evidence for dose selection and titration for future clinical development and clinical application in these population.
